Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 27, 2026, 12:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hormone Replacement Therapy Clear all
Recruiting No phase listed Observational

Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease

NCT01665326
View directory record Official record
Conditions
Pompe Disease
Interventions
Observational
Other
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2029
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Jun 27, 2026, 12:07 AM EDT
Not listed Phase 1Phase 2 Interventional

A Study of Cell Therapy for Subjects With Acute Kidney Injury Who Are Receiving Continuous Renal Replacement Therapy

NCT03015623
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
SBI-101, Sham
Biological · Device
Lead sponsor
Sentien Biotechnologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Allentown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 15, 2021 · Synced Jun 27, 2026, 12:07 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of Moclobemide, a Reversible MAO-A Inhibitor, as an Adjunct to Nicotine Replacement Therapy in Female Smokers

NCT01926626
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Nicotine Patch, Moclobemide
Drug
Lead sponsor
Jed E. Rose
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
Charlotte, North Carolina • Durham, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 22, 2017 · Synced Jun 27, 2026, 12:07 AM EDT
Completed Not applicable Interventional Results available

The Effect of Loop Diuretics on Severity and Outcome of Acute Kidney Injury

NCT01275729
View directory record Official record
Conditions
Acute Kidney Failure
Interventions
Furosemide
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
4
States / cities
San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced Jun 27, 2026, 12:07 AM EDT
Not yet recruiting Phase 3 Interventional Accepts healthy volunteers

iCanQuit Smoking Cessation Among Hispanic Adults

NCT06811038
View directory record Official record
Conditions
Cigarette Smoking-Related Carcinoma
Interventions
iCanQuit Smartphone App Smoking Cessation Program, Nicotine Gum, Nicotine Patch, Nicotine Lozenge, Survey Administration, Interview
Device · Drug · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
854 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Jun 27, 2026, 12:07 AM EDT
Completed No phase listed Observational Results available

Empowering Patients On Choices for Renal Replacement Therapy (Aim 1)

NCT01952600
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Not listed
Lead sponsor
Arbor Research Collaborative for Health
Other
Eligibility
18 Years and older
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 19, 2016 · Synced Jun 27, 2026, 12:07 AM EDT
Completed Phase 3 Interventional Results available

Study to Investigate Efficacy, Safety and Pharmacokinetics of BT595 in Subjects With PID

NCT02810444
View directory record Official record
Conditions
Primary Immunodeficiency Disease
Interventions
IgG Next Generation (BT595)
Biological
Lead sponsor
Biotest
Industry
Eligibility
2 Years to 75 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
9
States / cities
Birmingham, Alabama • Los Angeles, California • Centennial, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Jun 27, 2026, 12:07 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety, Tolerability and Pharmacokinetics of SBC-102 (Sebelipase Alfa) in Adult Participants With Lysosomal Acid Lipase Deficiency

NCT01307098
View directory record Official record
Conditions
Cholesterol Ester Storage Disease(CESD), Lysosomal Acid Lipase Deficiency, LAL-Deficiency
Interventions
Sebelipase alfa 0.35 mg/kg, Sebelipase alfa 1 mg/kg, Sebelipase alfa 3 mg/kg
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
Stanford, California • New York, New York • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 10, 2018 · Synced Jun 27, 2026, 12:07 AM EDT
Completed Phase 3 Interventional

Ferumoxytol Versus Oral Iron in the Treatment of Anemia in Hemodialysis Patients

NCT00233597
View directory record Official record
Conditions
Anemia
Interventions
ferumoxytol or oral iron
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
50
States / cities
Phoenix, Arizona • Tempe, Arizona • Los Angeles, California + 42 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2022 · Synced Jun 27, 2026, 12:07 AM EDT
Withdrawn No phase listed Observational

Starling/CRRT Observational Study

NCT05729048
View directory record Official record
Conditions
Hemodynamic Monitoring
Interventions
Starling
Device
Lead sponsor
Baxter Healthcare Corporation
Industry
Eligibility
18 Years to 95 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 13, 2023 · Synced Jun 27, 2026, 12:07 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Parent eReferral to Tobacco Quitline

NCT02997735
View directory record Official record
Conditions
Secondhand Smoke
Interventions
Quitline Delivered Treatment
Behavioral
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
18 Years and older
Enrollment
484 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 27, 2019 · Synced Jun 27, 2026, 12:07 AM EDT
Completed Phase 2 Interventional Results available

OPTION: A Trial to Assess the Safety & Efficacy of MS1819 in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis

NCT03746483
View directory record Official record
Conditions
Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF)
Interventions
MS1819, Porcine PERT
Drug
Lead sponsor
Entero Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
11
States / cities
Long Beach, California • Altamonte Springs, Florida • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2022 · Synced Jun 27, 2026, 12:07 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluating the Effects of Hormone Replacement Therapy on Brain Function (The WHIMS-MRI Study)

NCT00739869
View directory record Official record
Conditions
Stroke
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
65 Years to 90 Years · Female only
Enrollment
1,426 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 5, 2024 · Synced Jun 27, 2026, 12:07 AM EDT
Completed Phase 4 Interventional

Ceftaroline Pharmacokinetics in Continuous Renal Replacement Therapy

NCT04152694
View directory record Official record
Conditions
Infection During Renal Replacement Therapy, Critically Ill
Interventions
Ceftaroline levels in CRRT
Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 17, 2021 · Synced Jun 27, 2026, 12:07 AM EDT
Completed Not applicable Interventional

Safety of Stopping Pancreatic Enzyme Replacement Therapy in Children With Improved Pancreatic Function After Highly Effective Modulator Therapy

NCT07632768
View directory record Official record
Conditions
Cystic Fibrosis (CF), Pancreatic Insufficiency, Pancreas Disease, Exocrine Pancreatic Insufficiency, Exocrine Pancreatic Insufficiency in Subjects With Cystic Fibrosis, CFTR Gene Mutation
Interventions
Discontinuation of Pancreatic Enzyme Replacement Therapy
Drug
Lead sponsor
Indiana University
Other
Eligibility
0 Years to 18 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Jun 27, 2026, 12:07 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic (PK) Study to Compare the Absorption of Two Formulations of Transdermal Testosterone Spray and Intrinsa®

NCT01096329
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
Testosterone Spray 5% and 1%, Intrinsa® Patch and Testosterone Spray 5%, Intrinsa® Patch and Testosterone Spray 1%
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
45 Years to 65 Years · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2010
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 7, 2011 · Synced Jun 27, 2026, 12:07 AM EDT
Completed Phase 4 Interventional

Pilot Study Evaluating Doxercalciferol Replacement Therapy in Kidney Transplant Recipients

NCT00889629
View directory record Official record
Conditions
Chronic Kidney Disease, Kidney Transplantation
Interventions
Doxercalciferol, placebo, 25-OH Vitamin D3
Drug
Lead sponsor
Mariana Markell
Other
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Feb 21, 2019 · Synced Jun 27, 2026, 12:07 AM EDT
Completed Phase 3 Interventional Results available

Study of Subcutaneous Immunoglobulin in Patients With PID Requiring IgG Replacement Therapy

NCT00419341
View directory record Official record
Conditions
Primary Immune Deficiency
Interventions
Human Normal Immunoglobulin for Subcutaneous Administration
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
2 Years to 75 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
13
States / cities
Los Angeles, California • Centennial, Colorado • North Palm Beach, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Jun 27, 2026, 12:07 AM EDT
Completed Not applicable Interventional Results available

Tobacco Intervention in Primary Care Treatment Opportunities for Providers

NCT02096029
View directory record Official record
Conditions
Smoking, Smoking Cessation
Interventions
Nicotine Replacement Therapy (NRT) Sampling, Ask, Advise, Refer (physician brief advice)
Other · Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
1,278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Jun 27, 2026, 12:07 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

TRT as an Adjunctive ERAS Therapy in ESRD Patients Undergoing Kidney Transplantation

NCT07287800
View directory record Official record
Conditions
Hypogonadism, Male, End Stage Renal Disease (ESRD), Kidney Transplant
Interventions
Testosterone Replacement Therapy
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Jun 27, 2026, 12:07 AM EDT
Not yet recruiting Phase 4 Interventional

Testosterone Replacement Therapy in Hypogonadal Patients With Prostate Cancer Under Active Surveillance

NCT07278362
View directory record Official record
Conditions
Prostate Cancer, Hypogonadism, Male
Interventions
Testosterone cypionate
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older · Male only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
2
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Jun 27, 2026, 12:07 AM EDT
Not listed Phase 1Phase 2 Interventional

TRT in Combination With Electrical Stimulation and Standing: Effect on Muscle and Bone in Spinal Cord Injured Males

NCT02317640
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
Testosterone Gel applied by a pump, Stand Training, Electrical Stimulation
Drug · Other · Device
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years to 58 Years · Male only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 21, 2017 · Synced Jun 27, 2026, 12:07 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Risk Perception Among Quitting Smokers

NCT00384696
View directory record Official record
Conditions
Smoking
Interventions
Nicotine Replacement Therapy, Questionnaire
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 23, 2019 · Synced Jun 27, 2026, 12:07 AM EDT
Completed Phase 2Phase 3 Interventional

Humoral Immunodeficiency With Rituximab and Therapy With Subcutaneous Ig

NCT03211065
View directory record Official record
Conditions
Secondary Immune Deficiency
Interventions
20% subcutaneous immunoglobulin
Drug
Lead sponsor
Rochester General Hospital
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 18, 2021 · Synced Jun 27, 2026, 12:07 AM EDT